Osiris Therapeutics Inc., a Columbia-based biotechnology firm that had its stock delisted from the NASDAQ earlier this month, said Monday it completed a previously announced restatement of 2014 financial statements to show a bigger loss than initially reported
Cerecor, a Baltimore pharmaceutical development firm that went public in October 2015, has been notified that its stock no longer qualifies for listing on the Nasdaq market because it's been trading under $1 a share for 30 days.
Osiris Therapeutics Inc., the troubled Columbia-based biotechnology firm that saw its CEO resign last month, said Tuesday it has been notified of a failure to comply with rules for listing on the Nasdaq Stock Market.
But a plan announced Tuesday to guarantee the CEO's personal control is raising eyebrows as the $3 billion firm pursues global expansion. On Monday, Under Armour's board approved an unusual two-for-one stock split that would create a new class of stock without voting rights and give owners of each existing share of common stock one new share of Class C stock. It would preserve Plank's control even as he sells off shares.
This week 44 years ago, the Alan Shepard-commanded Apollo 14 landed on the moon, the stock market index Nasdaq was launched, "Love Story" was the No. 1 film at the box office and the following songs were the most popular in America, according to Billboard's Hot 100 chart archive.
The largest shareholder of The Men's Wearhouse Inc. is once again calling for the retailer to resume merger talks with Hampstead-based Jos. A. Bank Clothiers Inc. and hired a strategic adviser to help the effort.
As Jos. A. Bank Clothiers prepares to announce year-end and quarterly results this week, Zacks Investment Research has downgraded the retailer's stock to a strong sell rating, citing the company's January warning that fiscal year profit will be off 20 percent.